
Xin-Xin Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2681267/publications.pdf Version: 2024-02-01



XIN-XIN 7HANC

#	Article	IF	CITATIONS
1	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, The, 2020, 395, 507-513.	13.7	16,090
2	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9490-9496.	7.1	1,601
3	Phase-adjusted estimation of the number of Coronavirus Disease 2019 cases in Wuhan, China. Cell Discovery, 2020, 6, 10.	6.7	358
4	Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score. Frontiers in Microbiology, 2019, 10, 2752.	3.5	326
5	Coronavirus disease 2019 (COVID-19): a clinical update. Frontiers of Medicine, 2020, 14, 126-135.	3.4	309
6	Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients. EBioMedicine, 2020, 57, 102833.	6.1	307
7	Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet, The, 2022, 399, 2011-2012.	13.7	232
8	Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistence in Immunocompetent Mice. Journal of Virology, 2014, 88, 8045-8056.	3.4	81
9	N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. Journal of Hepatology, 2014, 60, 515-522.	3.7	77
10	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. Journal of Hepatology, 2021, 75, 454-461.	3.7	70
11	Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut, 2011, 60, 1269-1277.	12.1	69
12	Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Scientific Reports, 2017, 7, 43446.	3.3	68
13	Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discovery, 2022, 8, 4.	6.7	68
14	Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. Journal of Hepatology, 2009, 50, 895-905.	3.7	65
15	Predictive model for inflammation grades of chronic hepatitis B: Largeâ€scale analysis of clinical parameters and gene expressions. Liver International, 2017, 37, 1632-1641.	3.9	62
16	Serum <scp>WFA</scp> ⁺ â€M2 <scp>BP</scp> levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver International, 2017, 37, 35-44.	3.9	61
17	Characterization of antibody responses to SARS oVâ€2 in convalescent COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 2227-2233.	5.0	53
18	Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine, 2017, 19, 18-30.	6.1	51

#	Article	IF	CITATIONS
19	Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nature Communications, 2021, 12, 4144.	12.8	49
20	Estimation of reproduction numbers of COVID-19 in typical countries and epidemic trends under different prevention and control scenarios. Frontiers of Medicine, 2020, 14, 613-622.	3.4	45
21	Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19. Frontiers in Immunology, 2020, 11, 565278.	4.8	39
22	Comparison of Next-Generation Sequencing and Clone-Based Sequencing in Analysis of Hepatitis B Virus Reverse Transcriptase Quasispecies Heterogeneity. Journal of Clinical Microbiology, 2013, 51, 4087-4094.	3.9	37
23	Hepatitis B Virus Core Protein Sensitizes Hepatocytes to Tumor Necrosis Factor-Induced Apoptosis by Suppression of the Phosphorylation of Mitogen-Activated Protein Kinase Kinase 7. Journal of Virology, 2015, 89, 2041-2051.	3.4	36
24	A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection. EBioMedicine, 2020, 61, 103036.	6.1	34
25	Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Frontiers in Pharmacology, 2021, 12, 788558.	3.5	34
26	Differentially Expressed Intrahepatic Genes Contribute to Control of Hepatitis B Virus Replication in the Inactive Carrier Phase. Journal of Infectious Diseases, 2018, 217, 1044-1054.	4.0	30
27	Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12529-12530.	7.1	30
28	Comparison of Circulating, Hepatocyte Specific Messenger RNA and microRNA as Biomarkers for Chronic Hepatitis B and C. PLoS ONE, 2014, 9, e92112.	2.5	30
29	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 1788.	12.8	30
30	OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. Journal of Medical Virology, 2020, 92, 3596-3603.	5.0	28
31	ITGBL1 promotes cell migration and invasion through stimulating the TGFâ€Î² signalling pathway in hepatocellular carcinoma. Cell Proliferation, 2020, 53, e12836.	5.3	28
32	Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays. Cell Discovery, 2020, 6, 75.	6.7	27
33	Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection. Journal of Clinical Microbiology, 2015, 53, 2203-2214.	3.9	26
34	Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort. Science Bulletin, 2021, 66, 2312-2319.	9.0	26
35	Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults. Frontiers of Medicine, 2022, 16, 93-101.	3.4	21
36	Biodegradable mesoporous calcium–magnesium silicate-polybutylene succinate scaffolds for osseous tissue engineering. International Journal of Nanomedicine, 2015, 10, 6699.	6.7	18

#	Article	IF	CITATIONS
37	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatology International, 2019, 13, 260-269.	4.2	18
38	Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clinical Gastroenterology and Hepatology, 2020, 18, 196-204.e8.	4.4	18
39	Phase- and epidemic region-adjusted estimation of the number of coronavirus disease 2019 cases in China. Frontiers of Medicine, 2020, 14, 199-209.	3.4	18
40	Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins. Biotechnology and Applied Biochemistry, 2001, 34, 109.	3.1	17
41	Hepatitis C screening in hospitals: find the missing patients. Virology Journal, 2019, 16, 47.	3.4	17
42	Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant. Emerging Microbes and Infections, 2017, 6, 1-5.	6.5	16
43	Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. Journal of Clinical Virology, 2013, 57, 318-322.	3.1	15
44	Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. Scientific Reports, 2017, 7, 15658.	3.3	14
45	Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China. Microbial Drug Resistance, 2017, 23, 516-522.	2.0	13
46	Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1353-1357.	2.8	12
47	Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide. Scientific Reports, 2016, 6, 29391.	3.3	11
48	SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Frontiers of Medicine, 2022, 16, 185-195.	3.4	11
49	A comparative study on the characterization of hepatitis B virus quasispecies by clone-based sequencing and third-generation sequencing. Emerging Microbes and Infections, 2017, 6, 1-8.	6.5	10
50	Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. Microbial Drug Resistance, 2019, 25, 944-950.	2.0	10
51	A novel homozygous no-stop mutation in G6PC gene from a Chinese patient with glycogen storage disease type Ia. Gene, 2014, 536, 362-365.	2.2	9
52	Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferonâ€Î± treatment in HBeAgâ€positive chronic hepatitis B patients. Journal of Medical Virology, 2018, 90, 721-729.	5.0	9
53	Evaluation of optic canal anatomy and symmetry using CT. BMJ Open Ophthalmology, 2019, 4, e000302.	1.6	9
54	Effect of multiple mutations in the core promoter and pre-core/core region of hepatitis B virus genome on the response to interferon in e antigen-positive chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 393-398.	2.8	8

#	Article	IF	CITATIONS
55	Retrospective detection of SARS-CoV-2 in hospitalized patients with influenza-like illness. Emerging Microbes and Infections, 2020, 9, 1470-1473.	6.5	8
56	Quality Management for Point-Of-Care Testing of Pathogen Nucleic Acids: Chinese Expert Consensus. Frontiers in Cellular and Infection Microbiology, 2021, 11, 755508.	3.9	8
57	A missing piece of the puzzle in pulmonary fibrosis: anoikis resistance promotes fibroblast activation. Cell and Bioscience, 2022, 12, 21.	4.8	8
58	Genetic testing of <scp><i>UGT1A1</i></scp> in the diagnosis of Gilbert syndrome: The discovery of seven novel variants in the Chinese population. Molecular Genetics & Genomic Medicine, 2022, 10, e1958.	1.2	8
59	Epidemiological and clinical characteristics of three family clusters of COVID-19 transmitted by latent patients in China. Epidemiology and Infection, 2020, 148, e137.	2.1	7
60	Tandem Mass Tag-based quantitative proteomics analysis of metabolic associated fatty liver disease induced by high fat diet in mice. Nutrition and Metabolism, 2020, 17, 97.	3.0	7
61	Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist. Genome Biology, 2021, 22, 297.	8.8	7
62	Characteristics of CpG Islands and their quasispecies of full-length hepatitis B virus genomes from patients at different phases of infection. SpringerPlus, 2016, 5, 1630.	1.2	6
63	Genome-wide characterization of the seasonal H3N2 virus in Shanghai reveals natural temperature-sensitive strains conferred by the I668V mutation in the PA subunit. Emerging Microbes and Infections, 2018, 7, 1-15.	6.5	6
64	Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients. Journal of Clinical Microbiology, 2020, 58, .	3.9	6
65	A Novel FLCN Intragenic Deletion Identified by NGS in a BHDS Family and Literature Review. Frontiers in Genetics, 2021, 12, 636900.	2.3	6
66	Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. Journal of Clinical and Translational Hepatology, 2019, 7, 1-9.	1.4	6
67	An integrated software for virus community sequencing data analysis. BMC Genomics, 2020, 21, 363.	2.8	5
68	A blood-based 22-gene expression signature for hepatocellular carcinoma identification. Annals of Translational Medicine, 2020, 8, 195-195.	1.7	5
69	Prognostic value of antiâ€HBc quantification in hepatitis B virus related acuteâ€onâ€chronic liver failure. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1291-1299.	2.8	5
70	Pegâ€interferon alpha addâ€on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAgâ€positive chronic hepatitis B naÃīve patients. Journal of Viral Hepatitis, 2021, 28, 1381-1391.	2.0	4
71	Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerging Microbes and Infections, 2021, 10, 842-851.	6.5	4
72	Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 285-300.	3.7	3

#	Article	IF	CITATIONS
73	Next generation sequencing identified novel heterozygous nonsense mutation in CNGB1 gene associated with retinitis pigmentosa in a Chinese patient. Oncotarget, 2017, 8, 88345-88350.	1.8	3
74	The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report. Infection and Drug Resistance, 2021, Volume 14, 1013-1017.	2.7	2
75	LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. Clinical Proteomics, 2014, 11, 44.	2.1	1
76	Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. Journal of Clinical Virology, 2015, 72, 88-94.	3.1	1
77	Serum Glycocholic Acid-to-Total Bile Acid Ratio Is Independently Associated with Nonalcoholic Fatty Liver Disease: A Retrospective Cross-Sectional Study. BioMed Research International, 2021, 2021, 1-10.	1.9	1
78	Congenital dyserythropoietic anemia and drug‑induced liver injury present as bland cholestasis: A case report. Experimental and Therapeutic Medicine, 2021, 21, 456.	1.8	1
79	Hepatitis B virus middle surface antigen loss promotes clinical variant persistence in mouse models. Virulence, 2021, 12, 2868-2882.	4.4	1
80	Protective Role of Rheumatic Diseases Against Hepatitis B Virus Infection and Human Leukocyte Antigen B27 Highlighted. Frontiers in Medicine, 2022, 9, 814423.	2.6	1
81	Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	1.4	1
82	Functional analysis of variants in DMD exon/intron 10 predicted to affect splicing. Journal of Human Genetics, 2022, 67, 495-501.	2.3	1
83	Pegylated interferonâ€Î±â€2b combined with tenofovir disoproxil fumarate, granulocyteâ€macrophage colonyâ€stimulating factor, and hepatitis B vaccine treatment for naÃ∙ve HBeAgâ€positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study. Journal of Medical Virology, 0, , .	5.0	1